Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3806
Abstract: Metastatic castration‐resistant prostate cancer (mCRPC) patients have a poor prognosis, and curcumin is known to have antineoplastic properties. On the basis of previous phase I and phase II studies, we investigated whether the association of… read more here.
Keywords: phase; docetaxel plus; metastatic castration; castration resistant ... See more keywords
The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "World Journal of Surgery"
DOI: 10.1007/s00268-019-05000-3
Abstract: BackgroundDefinitive chemoradiotherapy (CRT), used for treatment of patients with an initial diagnosis of unresectable locally advanced esophageal cancer, has led to unsatisfactory long-term prognosis. Moreover, CRT can lead to esophageal fistula, perforation, and strictures. Therefore,… read more here.
Keywords: treatment; group; docetaxel plus; advanced esophageal ... See more keywords
TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2021.08.008
Abstract: BACKGROUND Docetaxel (DOCE) is a standard of care in metastatic castration-resistant prostate cancer (mCRPC). Several retrospective studies suggested a decrease in Prostate Cancer incidence and mortality with metformin (MET). MET has also demonstrated anti-tumor activity… read more here.
Keywords: prostate cancer; docetaxel plus; metastatic castration; castration resistant ... See more keywords
Real-world data of docetaxel-induced liver injury among hospitalized patients in Wuhan, China: A retrospective analysis
Sign Up to like & getrecommendations! Published in 2025 at "Medicine"
DOI: 10.1097/md.0000000000042881
Abstract: This study aims to analyze the risk factors of docetaxel-induced liver injury to provide evidence for the clinical prevention and treatment of docetaxel-induced liver injury. A retrospective analysis of patients who received docetaxel chemotherapy regimen… read more here.
Keywords: docetaxel induced; liver injury; induced liver; docetaxel ... See more keywords
Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14236
Abstract: BACKGROUND Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non-small-cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second-line treatment after chemoimmunotherapy is… read more here.
Keywords: docetaxel plus; cancer; chemoimmunotherapy; plus ramucirumab ... See more keywords
TAXOMET: A French prospective multicenter randomized controlled phase II study comparing docetaxel plus metformin versus docetaxel plus placebo in mCRPC.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.5004
Abstract: 5004 Background: Docetaxel (DOCE) is a standard of care in metastatic castration-resistant prostate cancer (mCRPC). Several retrospective cohort studies suggest a decrease in PC incidence and mortality with metformin (MET). MET has also demonstrated anti-tumor… read more here.
Keywords: docetaxel plus; mcrpc; placebo; randomized controlled ... See more keywords
Docetaxel plus cis-platinum chemotherapy for the posterior line treatment of metastatic castrate-resistant prostate cancer with elevated neuron specific enolase.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e17042
Abstract: e17042 Background: This Study is to figure out the efficacy of docetaxel plus cis-platinum (DC) chemotherapy as the posterior line treatment for metastatic castrate-resistant prostate cancer (mCRPC) with elevated neuron specific enolase (NSE). Methods: We… read more here.
Keywords: chemotherapy; plus cis; platinum chemotherapy; cis platinum ... See more keywords
Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.01295
Abstract: Objective: Our study aimed to compare the efficacy and toxicity of two chemotherapy regimens, gemcitabine plus cisplatin (GP) vs. docetaxel plus, fluorouracil plus cisplatin (TPF), in metastatic nasopharyngeal carcinoma (NPC) patients. Methods: We retrospectively enrolled… read more here.
Keywords: chemotherapy; plus fluorouracil; docetaxel plus; plus cisplatin ... See more keywords
A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2025.1468928
Abstract: Background The last decade saw the emergence of several new systemic therapies for metastatic hormone-sensitive prostate cancer (mHSPC). While these treatments demonstrated similar efficacy in indirect comparisons, comparisons of safety outcomes are needed to help… read more here.
Keywords: systemic treatments; safety; network; aap plus ... See more keywords